Insilico Medicine (03696.HK): ISM6331 Granted FDA Fast Track Designation for Advanced Mesothelioma Treatment
NewTimeSpace News: On July 29, 2026, Insilico Medicine (03696.HK) issued an announcement that ISM6331, an innovative AI-driven pan-TEAD inhibitor self-developed by the firm, has secured Fast Track Designation from the FDA for the treatment of advanced mesothelioma.
As disclosed in the announcement, ISM6331 is a potent pan-TEAD inhibitor indicated for adult patients with unresectable malignant pleural mesothelioma whose disease has progressed following prior treatment with anti-PD-1 antibodies and platinum-based chemotherapy. The drug obtained FDA Orphan Drug Designation back in 2024, and the first patient dosing of its global multi-centre Phase I clinical trial was completed in January 2025.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Insilico Medicine (03696.HK): Strategic Partnership with Takeda for AI-Driven Drug Discovery with Total Value Up to USD 600 Million
- Insilico Medicine (03696.HK): Two Core Senior Executives Voluntarily Extend Lock-up Period to June 2027
- InSilico Medicine (03696.HK) and Bora Pharmaceuticals Announce Strategic Alliance with Potential Value Exceeding US$2.5 Billion
- INSILICO (03696.HK): Enters CNS Drug R&D Collaboration with Cosmo Pharmaceutical, Potential Milestone Payments Up to Approximately RMB1.2 Billion
